G. Dannberg

Heterotopic transcatheter tricuspid valve implantation: first-in-man application of a novel approach to tricuspid regurgitation

AIMS Transcatheter treatment of heart valve disease is well established today. However, for the treatment of tricuspid regurgitation (TR), no effective catheter-based approach is available. Herein, we report the first human case description of transcatheter treatment of severe TR in a 79-year-old patient with venous congestion and associated non-cardiac diseases. In this patient, surgical treatment had been declined and pharmacological therapy had been ineffective. After ex vivo and animal studies, the treatment of TR was performed by percutaneous caval valve implantation. METHODS AND RESULTS In a transcatheter approach through the right femoral vein, a custom-made self-expanding heart valve was implanted into the inferior vena cava (IVC). The device was anchored in the IVC at the cavoatrial junction with the level of the valve aligned immediately above the hepatic inflow and protruding into the right atrium. After deployment, excellent valve function was observed resulting in a marked reduction in caval pressure and an abolition of the ventricular wave in the IVC. Sequential echocardiographic exams over a follow-up period of 8 weeks confirmed continuous device function without paravalvular leakage or remaining venous regurgitation. The patient experienced improved physical capacity and was able to resume off-bed activities. There was no recurrence of right heart failure during follow-up and a partial reduction of ascites. The patient was discharged from hospital into a rehabilitation programme. CONCLUSION Transcatheter treatment of severe TR by caval valve implantation is feasible resulting in an immediate abolition of IVC regurgitation and mid-term clinical improvement. Thus, in selected non-surgical patients, caval valve implantation may become a therapeutic option to treat venous regurgitation and improve associated non-cardiac diseases. Further confirmatory experience with longer follow-up is required to evaluate the long-term clinical benefit of the procedure as well as potential deleterious effects.

Transesophageal left ventricular posterior wall potential in heart failure patients with biventricular pacing / Transösophageales linksventrikuläres Potenzial der posterioren Wand bei Patienten mit Herzinsuffizienz und biventrikulärer Stimulation

Abstract Introduction: Biventricular (BV) pacing is an established therapy for heart failure (HF) patients with intraventricular conduction delay, but not all patients improved clinically. We investigated the interventricular delay (IVD) by means of the transesophageal left ventricular posterior wall potential (LVPWP). Materials and methods, and Results: A total of 18 HF patients (age 62±9 years; 15 males) with NYHA class 3.1±0.3, LV ejection fraction 22±7%, left bundle branch block and a QRS duration (QRSD) of 171±27 ms were analyzed using transesophageal LVPWP before implantation of a BV pacing device. The median follow up was 14±14 months. In 14 responders, IVD was 81±25 ms with a QRSD/IVD ratio of 2.2±0.3 with reclassification of NYHA class 3.1±0.3 to 2.0±0.5 (p<0.001) and an increase in LV ejection fraction from 22±7% to 36±11% (p=0.001) during long-term BV pacing. In four non-responders, transesophageal IVD was significantly smaller at 30±11 ms (p=0.001). Conclusion: Transesophageal IVD may be a useful method to detect responders to BV pacing. Transesophageal LVPWP may be a simple and useful technique to detect clinical responders to BV pacing in HF patients. Zusammenfassung Einleitung: Die biventrikuläre (BV) Stimulation ist eine etablierte Therapie bei Patienten mit Herzinsuffizienz (HF) und intraventrikulärem Leitungsdelay, aber nicht alle Patienten verbessern sich klinisch. Wir haben das interventrikuläre Delay (IVD) mit dem transösophagealen linksventrikulären Potenzial der posterioren Wand (LVPWP) untersucht. Material und Methode und Ergebnisse: Elf HF-Patienten (Alter 62±9 Jahre; 15 Männer) mit NYHA Klasse 3,1±0,3, LV Ejektionsfraktion 22±7%, Linksschenkelblock und QRS-Dauer (QRSD) 171±27 ms wurden mit dem transösophagealen LVPWP vor Implantation eines BV Schrittmachers analysiert. Der Median der Nachuntersuchung betrug 14±14 Monate. Bei 14 Respondern betrug das IVD 81±25 ms mit einem QRSD/IVD Verhältnis von 2,2±0,3. Es verbesserte sich die NYHA Klasse von 3,1±0,3 auf 2,0±0,5 (p<0,001) und erhöhte sich die LV Ejektionsfraktion von 22±7 auf 36±11% (p=0,001) während der BV Stimulation über lange Zeit. Bei 4 Nonrespondern war das transösophageale IVD signifikant geringer mit 30±11 ms (p=0,001). Schlussfolgerung: Das transösophageale IVD stellt möglicherweise eine brauchbare Methode zur Erkennung von Respondern für die BV Stimulation dar. Das transösophageale LVPWP ist möglicherweise eine einfache und brauchbare Technik zur Erkennung von klinischen Respondern für die BV Stimulation bei HF-Patienten.

Electrophysiological evaluation of tachycardias using transesophageal pacing and recording.

VOLKMANN, H., ET AL: Electrophysiological Evaluation of Tachycardias Using Transesophageal Pacing and Recording. Programmed electrical stimulation of the heart to initiate and terminate tachycardia has been useful in the evaluation of supraventricular and ventricular tachyarrhythmias. A wide use of these procedures, however, failed because of the expense of the invasive approach as well as the lack of physician experience in smaller hospitals. These disadvantages of the invasive proceeding can be abolished by transesophageal pacing. In our study, supraventricular tachycardias were initiated by programmed transesophageal atrial stimulation in 251 patients [AV node reentry in 75 patients, orthodromic AV reciprocating tachycardia using accessory pathway in 97 patients, antidromic AV reciprocating tachycardia in 11 patients, and atrial reentry in 39 patients). The stimulation protocol included one and two extrastimuli during sinus rhythm and after a pacing drive at different cycle lengths. The electrophysiological mechanism of tachycardias was determined by surface ECG, VA interval (esophageal lead), initiation mode at programmed transesophageal stimulation and by behavior of AV conduction and refractoriness. In 29 patients the mechanism of tachycardia was not clear. Invasive electraphysiological study was done in 219 of these 251 patients. In only nine patients, the supported mechanism of tachycardia was not confirmed by invasive investigation. In 11 patients, the etectrophysiological mechanism remained uncertain. In conclusion, the noninvasive transesophageal pacing is an appropriate method for evaluation of supraventricular tachycardia. It allows serial drug testing in a simple manner for finding an effective antiarrhythmic treatment.

Termination of Tachycardias by Transesophageal Electrical Pacing

To evaluate the therapeutic significance of noninvasive transesophageal pacing for termination of tachycardias the method of rapid atrial or ventricular transesophageal pacing was used in 233 patients with different tachycardiac arrhythmias. We were able to terminate atrial flutter in 136 of 162 patients by transesophageal rapid atrial stimulation (conversion to sinus rhythm in 75 cases, induction of atrial fibrillation in 61 cases). Atrial tachycardias were interrupted in 17 of 23 patients (sinus rhythm in 11 cases, atrial fibrillation in six cases). AV reciprocating/AV nodal supravenrricular reentry tachycardias were terminated in 62 of 63 patients (sinus rhythm in 58 cases, atrial fibrillation in four cases). By transesophageal rapid ventricular pacing ventricular tachycardias could be terminated in ten of 15 patients. The success rate of transesophageal pacing was influenced by the pacing rate, by the type of tachycardiac arrhythmia inclusive by the type of atrial flutter and by the tachycardias cycle length. Because the success rates are comparable with invasive technique and the procedure is simpler, the noninvasive transesophageal antitachycardiac pacing should be respected as the method of the first choice in patients with supraven‐tricular tachycardias.

Bundle Branch Reentrant Tachycardia Treated by Transvenous Catheter Ablation of the Right Bundle Branch

Recurrent episodes of ventricuiar tachycardia not responding to medical treatment occurred in a 56‐year‐old man. Electrophysiological investigation showed ventricular tachycardia due to bundle branch reentry. Using a method similar to catheter ablation of the atrioventricular junction, ablation of the right bundle branch was performed by an electrical shock of 250 joules. While before the ablation ventricular tachycardia occurred several times a day and its induction by programmed ventricular stimulation was facilitated by the administration of antiarrhythmic drugs, no initiation of ventricular tachycardia was possible after ablation of the right bundle branch. Over a follow‐up of 30 months the patient has not suffered from tachycardia and the right bundle branch block persists.

Termination of atrial flutter by directed transesophageal atrial pacing during transesophageal echocardiography / Terminierung von Vorhofflattern mit gerichteter transösophagealer Vorhofstimulation bei transösophagealer Echokardiographie

Abstract Introduction: The purpose of this study was to evaluate termination of atrial flutter (AFL) by directed rapid transesophageal atrial pacing (TAP) with and without simultaneous transesophageal echocardiography (TEE) performed using a novel TEE tube electrode. Materials and methods, and Results: A total of 16 AFL patients (age 63±12 years; 13 males) with mean AFL cycle length of 224±24 ms (n=12) and mean ventricular cycle length of 448±47 ms (n=12) were analyzed using either an esophageal TO electrode (n=10) or a novel TEE tube electrode consisting of a tube with four hemispherical electrodes that is pulled over the echo probe (n=6). AFL could be terminated by directed rapid TAP using an esophageal TO electrode, leading to induction of atrial fibrillation (AF) (n=6), induction of AF and spontaneous conversion to sinus rhythm (SR) (n=3), and with conversion to SR (n=1). AFL could also be terminated by directed rapid TAP using the TEE tube electrode, with induction of AF (n=3) or induction of AF and spontaneous conversion to SR (n=3). Conclusion: AFL can be terminated by directed rapid TAP with hemispherical electrodes with and without simultaneous TEE. TAP with the directed TEE tube electrode is a safe, simple, and useful method for terminating AFL. Zusammenfassung Einleitung: Die Terminierung von Vorhofflattern (AFL) mit gerichteter hochfrequenter transösophagealer Vorhofstimulation (TAP) wurde mit und ohne simultane transösophageale Echokardiographie (TEE) mit einer neuen TEE-Schlauchelektrode evaluiert. Material und Methode und Ergebnisse: 16 AFL Patienten (Alter 63±12 Jahre; 13 Männer) mit einer mittleren AFL-Periodendauer von 224±24 ms (n=12) und einer mittleren ventrikulären Periodendauer von 448±47 ms (n=12) wurden mittels Ösophaguselektrode „TO” (n=10) oder neuer „TEE-Schlauchelektrode”, die aus einem Schlauch mit 4 halbkugelförmigen Elektroden besteht und über die Echokardiographiesonde gezogen wird (n=6), analysiert. AFL konnte mit gerichteter hochfrequenter TAP und TO-Elektrode durch Induktion von Vorhofflimmern (AF) (n=6), Induktion von AF mit spontaner Konversion in den Sinusrhythmus (SR) (n=3) und Konversion in den SR (n=1) terminiert werden. AFL konnte mit gerichteter hochfrequenter TAP und TEE-Schlauchelektrode durch Induktion von AF (n=3) und Induktion von AF mit spontaner Konversion in den SR (n=3) terminiert werden. Schlussfolgerung: AFL kann durch gerichtete hochfrequente TAP mit halbkugelförmigen Elektroden mit und ohne simultane TEE terminiert werden. TAP mit der gerichteten TEE-Schlauchelektrode ist eine sichere, einfache und praktikable Methode zur Terminierung von AFL.

Unexpanded, irretrievable stent in the proximal right coronary artery: successful management with stent graft implantation.

Stent loss and failure of retrieval are rare; nevertheless, complications have to be taken into account during percutaneous coronary intervention. Here we report a case of an unexpanded, irretrievable Palmaz‐Schatz stent in the proximal right coronary artery near to the ostium and the successful management by implanting a synthetic stent graft. Cathet. Cardiovasc. Intervent. 46:344–349, 1999.

Association of inverted Takotsubo cardiomyopathy with postpartum pneumo-mediastinum: when a “broken lung” meets a “broken heart”

Association of inverted Takotsubo cardiomyopathy with postpartum pneumo-mediastinum 1 1 3 Six hours after an uneventful delivery, a 30-year-old primiparous woman complained of pleuritic-type chest pain and sense of immense apprehension. Initially, Troponin-I (Tn-I) level was normal (0.01 ng/mL), but D-dimer was elevated (1200 μg/L). Pulmonary embolism was excluded by a computed tomography scan, which revealed signs of pneumo-mediastinum and subcutaneous emphysema (a). Shortly after, due to raised Tn-I level to 1.88 ng/mL and T-wave inversion in anterior precordial leads, she was referred to us. Angiography disclosed normal coronary arteries (b, c), but wall-motion abnormalities (WMA) in basal segments were noted (d). Cardiac magnetic resonance imaging excluded late gadolinium enhancement (e, f ). Transthoracic echocardiography showed significant hypoto akinesis of basal inferior and posterior left ventricular wall and dyskinesis of basal anteroseptal segments (g, h). Estimated ejection fraction (EF) by 3D quantification was 27 % (i, j). This peculiar pattern of WMA with clinical settings and normal coronary arteries was consistent with reversed/ inverted Takotsubo cardiomyopathy (ITC). She received appropriate management with beta-blockers and angiotensin-converting enzyme inhibitors. EF was completely normalized after 1 month (k, l). To the best of our knowledge, this association of pneumo-mediastinum and ITC has not been reported. Notably, ITC occurs more frequently in younger age and is more commonly associated with mental stress than the typical forms of Takotsubo cardiomyopathy.

Electrical Right and Left Cardiac Atrioventricular and Left Atrial Delay in Cardiac Resynchronization Therapy Responder and Non-responder with Sinus Rhythm

Cardiac resynchronization therapy (CRT) with hemodynamic optimized biventricular pacing is an established therapy for heart failure patients with sinus rhythm, reduced left ventricular ejection fraction and wide QRS complex. The aim of the study was to evaluate electrical right and left cardiac atrioventricular delay and left atrial delay in CRT responder and non-responder with sinus rhythm. Methods: Heart failure patients with New York Heart Association class 3.0 ± 0.3, sinus rhythm and 27.7 ± 6.1% left ventricular ejection fraction were measured by surface ECG and transesophageal bipolar left atrial and left ventricular ECG before implantation of CRT devices. Electrical right cardiac atrioventricular delay was measured between onset of P wave and onset of QRS complex in the surface ECG, left cardiac atrioventricular delay between onset of left atrial signal and onset of left ventricular signal in the transesophageal ECG and left atrial delay between onset and offset of left atrial signal in the transesophageal ECG. Results: Electrical atrioventricular and left atrial delay were 196.9 ± 38.7 ms right and 194.5 ± 44.9 ms left cardiac atrioventricular delay, and 47.7 ± 13.9 ms left atrial delay. There were positive correlation between right and left cardiac atrioventricular delay (r = 0.803 P < 0.001) and negative correlation between left atrial delay and left ventricular ejection fraction (r = −0.694 P = 0.026) with 67% CRT responder. Conclusions: Transesophageal electrical left cardiac atrioventricular delay and left atrial delay may be useful preoperative atrial desynchronization parameters to improve CRT optimization.

Electrical interventricular delay and left ventricular delay in right ventricular pacemaker pacing before upgrading to cardiac resynchronization therapy

Abstract Cardiac resynchronization therapy with biventricular pacing is an established therapy for heart failure patients with sinus rhythm, reduced left ventricular ejection fraction and electrical ventricular desynchronization. The aim of the study was to evaluate electrical interventricular delay and left ventricular delay in right ventricular pacemaker pacing before upgrading to cardiac resynchronization therapy. Heart failure patients with right ventricular pacing, DDD pacemaker, DDD defibrillator and 24.5 ± 4.9 % left ventricular ejection fraction were measured by surface ECG and transesophageal bipolar left ventricular ECG before upgrading to cardiac resynchronization therapy. Interventricular and intraventricular desynchronization in right ventricular pacemaker pacing were 228.2 ± 44.8ms QRS duration, 86.5 ± 32.8ms interventricular delay and 94.4 ± 23.8ms left ventricular delay. Cardiac resynchronization therapy was optimized by impedance cardiography. Transesophageal electrical interventricular delay and left ventricular delay in right ventricular pacemaker pacing may be additional useful ventricular desynchronization parameters to improve patient selection for upgrading right ventricular pacemaker pacing to cardiac resynchronization therapy.